非晚期年龄相关性黄斑变性的最小结局指标集:TRACER(中期年龄相关性黄斑变性)研究组的德尔菲共识声明
TRACER研究组通过结构化德尔菲共识流程,由全球专家经六轮匿名调查与面对面会议,为非晚期年龄相关性黄斑变性(AMD)制定最小结局指标集。共识确定五个主要部分并批准28项最小结局指标,其中24项为必填、其余为可选;5项仅基线采集,12项每年评估变化,剩余项每次临床评估采集。该指标集可用于未来真实世界数据登记,以收集全球范围全面且纵向的临床数据。
要点
- 共识确定非晚期AMD最小结局指标集共28项,其中24项为必填、其余为可选。
- 五个主要部分为人口学特征、健康因素、功能、影像和临床结局。
- 5项仅基线采集,12项每年评估变化,剩余项每次临床评估采集。
核心结论
- 新定义的非晚期AMD最小结局指标集可用于未来真实世界数据收集登记,旨在全球范围收集全面且纵向广泛的临床数据。
- 该指标集可能有助于阐明非晚期AMD的自然进展及其对新疗法的反应。
研究设计与样本
- 由治疗结局登记、影像、营养及其他AMD领域全球专家组成专家组,开展结构化德尔菲共识流程。
- 专家匿名回答一系列调查,每轮后举行面对面会议讨论汇总结果;每轮前由协调人向组成员分享支持性文献。
- 共进行六轮直至达成正式共识,最终基于专家间一致程度创建共识文件。
主要发现
- 识别出五个主要部分:人口学特征、健康因素、功能、影像和临床结局。
- 随后制定并由全体成员批准28项最小结局指标集。
- 基于各条目优先级,24项被指定为必填,其余被视为可选。
- 5项仅需在基线时采集,12项需每年评估变化,剩余项须在每次临床评估时采集。
关键数值与推荐
- 最小结局指标集共28项,其中24项为必填、其余为可选。
- 5项仅基线采集,12项每年评估变化,剩余项每次临床评估采集。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The purpose of this study was to define a minimum set of outcome measures for patients affected by non-advanced age-related macular degeneration (AMD). METHODS: A structured Delphi consensus process was conducted by a panel of worldwide experts in treatment outcome registries, imaging, nutrition and other AMD aspects. The experts answered anonymously to a series of surveys, each followed by a face-to-face meeting to discuss the pooled results. Supporting literature was shared among the group members by a facilitator before each round. Finally, all the results were discussed and the consensus document was created based on the level of agreement between experts. RESULTS: Six rounds were conducted until a formal consensus was achieved. Five main sections were identified: demographic characteristics, health factors, functional, imaging and clinical outcomes. A minimum set of 28 outcome measures was subsequently developed and approved by all members. Based on the priority of various items, 24 fields were designated as mandatory, while the remaining were deemed optional. Five items are required only at baseline, 12 are to be assessed annually for changes and the remaining 0 1must be collected at each clinical assessment. CONCLUSION: This newly defined minimum set of outcome measures for non-advanced AMD could be employed in future real-world data collection registries aimed at gathering comprehensive and longitudinally extensive clinical data on a global scale. This may help to elucidate the natural progression of non-advanced AMD and its response to new therapies.
引用
- Cozzi M, Zweifel S, Balaskas K, et al. Minimum set of outcome measures for non-advanced age-related macular degeneration: a Delphi consensus statement by the TRACER (intermediate age-related macular degeneration) study group. Br J Ophthalmol. 2026. PMID: 41062254. doi:10.1136/bjo-2025-327744
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。